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AbstrAct
Background Form 1 of the European Society for 
Medical Oncology- Magnitude of Clinical Benefit Scale 
(ESMO- MCBS) serves to grade therapies with curative 
intent. Hitherto only few trials with curative intent 
have been field tested using form 1. We aimed to 
evaluate the applicability of the scale and to assess the 
reasonableness of the generated scores in early colon 
cancer, in order to identify shortcomings that may be 
rectified in future amendments.
Methods Adjuvant studies were identified in PubMed, 
Food and Drug Administration and European Medicines 
Agency registration sites, as well as ESMO and National 
Comprehensive Cancer Network guidelines. Studies 
meeting inclusion criteria were graded using form 1 of the 
ESMO- MCBS V.1.1 and field tested by ESMO Colorectal 
Cancer Faculty. Shortcomings of the scale were identified 
and evaluated.
Results Eighteen of 57 trials and 7 out of 14 meta- 
analyses identified met criteria for ESMO- MCBS V.1.1 
grading. In stage III colon cancer, randomised clinical 
trials and meta- analyses of modulated 5- fluorouracil 
(5- FU) based chemotherapy versus surgery scored ESMO- 
MCBS grade A and randomised controlled trials (RCTs) 
and meta- analyses comprising oxaliplatin added to this 
5- FU backbone showed a more modest additional overall 
survival benefit (grade A and B). For stage II colon cancer, 
the findings are less consistent. The fluoropyrimidine 
trials in stage II were graded ‘no evaluable benefit’ but the 
most recent meta- analysis demonstrated a 5.4% survival 
advantage after 8 years follow- up (grade A). RCTs and a 
meta- analysis adding oxaliplatin demonstrated no added 
benefit. Exploratory toxicity evaluation and annotation 
was problematic given inconsistent toxicity reporting and 
limited results of late toxicity. Field testers (n=37) reviewed 
the scores, 25 confirmed their reasonableness, 12 found 
them mostly reasonable. Moreover, they identified the 
inability of crediting improved convenience in non- 
inferiority trials as a shortcoming.
Conclusion Form 1 of the ESMO- MCBS V.1.1 provided 
very reasonable grading for adjuvant colon cancer studies.
IntRoduCtIon
Colorectal cancer is the third most common 
tumour in men, the second in women and 
second place in cancer- related cause of death 
in the world.1 Mortality has declined over the 
years for several reasons, including colorectal 
cancer screening and more effective systemic 
therapies in both the adjuvant setting and 
metastatic disease.1
Adjuvant therapies for colon cancer have 
evolved over the past 40 years. Early studies 
failed to show overall survival (OS) benefit of 
single agent therapy including 5- fluorouracil 
(5- FU) monotherapy compared with surgery 
Click here to listen to the Podcast
Key questions
What is already known about this subject?
 ► Form 1 of the European Society for Medical 
Oncology- Magnitude of Clinical Benefit Scale 
(ESMO- MCBS) serves to grade therapies with cu-
rative intent. Hitherto only few trials with curative 
intent have been field tested using form 1.
What does this study add?
 ► We evaluated the applicability of the scale and as-
sessed the reasonableness of the generated scores 
in early colon cancer. Form 1 of the ESMO- MCBS 
V.1.1 provided very reasonable grading for adjuvant 
colon cancer studies. Our exploratory analysis indi-
cated that toxicity annotation is feasible but that the 
prevailing convention of physician reported toxicity 
may underestimate the true level of patient burden 
from both acute and late toxicity. The inability of 
crediting improved convenience in non- inferiority 
trials was identified as a shortcoming.
How might this impact on clinical practice?
 ► Future revisions of form 1 of the ESMO- MCBS will be 
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Figure 1 CONSORT diagram forRCTs and meta- analyses 
eligible for analysis
DFS, disease- free survival; ESMO- MCBS, European 
Society for Medical Oncology- Magnitude of Clinical Benefit 
Scale; MOF, Lomustine, Vincristine,and 5- Fluorouracil; OS, 
overall survival; PVI, portal vein infusion; RCT, randomised 
controlled trial; UFT, uracil and tegafur.
alone.2 Adjuvant leucovorin modulated 5- FU (5- FU/LV) 
did, however, improve relative OS, but not absolute OS due 
to the increased incidence, and has been the standard of 
care since the mid- nineties. As of 2004, standard adjuvant 
therapy consists of a 5- FU/LV- based backbone to which 
oxaliplatin was added. Oxaliplatin did improve disease- free 
survival (DFS) and OS in stage III patients but it commonly 
caused substantial late toxicity (LT) with peripheral sensory 
neurotoxicity (PSN).3 Other agents including irinotecan, 
cetuximab and bevacizumab tested in the adjuvant setting, 
failed to show additional OS benefit.4–11
The European Society for Medical Oncology (ESMO) 
has developed a validated and reproducible tool to assess 
the magnitude of clinical benefit of anticancer thera-
pies of solid tumours. The ESMO- Magnitude of Clin-
ical Benefit Scale (ESMO- MCBS) was initially published 
in 201512 and a revised V.1.1 was issued in 2017.13 The 
ESMO- MCBS incorporates different grading approaches 
for interventions with either curative intent, such as 
adjuvant treatment in colon cancer or with non- curative 
intent. Form 1 has been developed for assessing new 
approaches to adjuvant therapy or new potentially cura-
tive therapies. The scale ranges from A to C, with grades 
A and B representing a substantial level of clinical 
benefit.12 13 Currently, form 1 does not apply penalties 
for toxicity. However, patient advocates in consultation 
with the ESMO- MCBS working group have suggested that 
toxicity annotations should be introduced for treatments 
with a high prevalence of strong acute toxicity (AT) or LT 
and this is currently under consideration.
The validity of the ESMO- MCBS is predicated on adher-
ence to the public policy ethical standard of ‘account-
ability for reasonableness’.12–15 Whereas the grading of 
treatments of advanced and incurable cancer using forms 
2a, b, c and 3 of the ESMO- MCBS has been extensively field 
tested and reviewed for reasonableness, hitherto only 13 
trials with curative intent, including adjuvant therapies, 
have been field tested using form 1.16 The main purpose 
was to evaluate the applicability of the scale in adjuvant 
colon cancer trials and further assess the reasonableness 
of the generated scores, in order to identify shortcomings 
that may be rectified in future amendments.
MetHods
Randomised controlled trials (RCTs) and meta- analyses 
in the adjuvant treatment of stage II/III colon cancer, 
published since the review of negative studies by Buyse 
et al2 up to September 2019 were identified. Data were 
collected by electronic searches of PubMed (medical head-
ings “colonic neoplasms” OR “colorectal neoplasms”, and 
the text words “adjuvant therapy” OR “adjuvant chemo-
therapy” OR “early colon cancer”) and by a manual review 
of Food and Drug Administration and European Medi-
cines Agency registration sites and ESMO and National 
Comprehensive Cancer Network guidelines.3 17 Refer-
ence lists of included studies were also analysed.
We included also trials that investigated regimens, 
which are currently seen as obsolete, to ensure the most 
comprehensive overview of the treatment of early colon 
cancer over three decades. These obsolete regimens often 
serve as the control arm in newer trials. Furthermore, 
scoring these older trials might give valuable informa-
tion regarding the applicability of the scale and identify 
possible shortcomings. Trials investigating adjuvant treat-
ment regimens that resulted in only negative results were 
excluded from the analysis. However, a trial with negative 
results per se, if the regimen investigated had positive 
outcome in other trials, was not an exclusion criterion. 
In addition, trials including rectal cancer without a 
predefined colon cancer subgroup, were excluded from 
the analysis since radiotherapy is instrumental in (neo)
adjuvant rectal cancer treatment which would make 
it difficult to assess the impact of chemotherapy. Meta- 
analyses that were not scoreable by the ESMO- MCBS scale 
were excluded for analysis as well (Consolidated Stan-
dards of Reporting Trials (CONSORT) diagram figure 1).
All studies meeting the inclusion and exclusion criteria 
were graded using form 1 of the ESMO- MCBS V.1.1 based 
on OS or DFS results. Additionally, for non- inferiority 
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life (QoL) and costs. If there were up to three predefined 
subgroups included in the trial and there was an appro-
priate adjustment for multiplicity, these subgroups were 
graded individually. Trials that did not meet the criteria 
for scoring due to insufficient benefit (negative studies) 
have been designated as trials with ‘no evaluable benefit’ 
(NEB). Negative non- inferiority (NNI) studies were 
labelled as NNI. Extracted data and grading were reviewed 
by the ESMO- MCBS Working Group for accuracy.
An exploratory analysis of reported toxicity data was 
undertaken to determine the feasibility of toxicity anno-
tations. Side effects during treatment or within 3 months 
after treatment completion were defined as AT. LT was 
defined as all events that occurred 3 months after treat-
ment completion in accordance with Common Toxicity 
Criteria.18 AT as well as LT was annotated as overall less (-), 
equal (=) or more (+) toxicity for the intervention versus 
the control group. When there is insufficient data reported 
to draw conclusions, not reported (NR) is annotated.
The scores generated in this field testing were reviewed 
by the ESMO Gastro- Intestinal Tumours Faculty for 
reasonableness.
Results
The literature search yielded 57 RCTs and 14 meta- analyses, 
with 18 RCTs and 7 meta- analyses finally found eligible and 
were included in the analysis. Reasons for exclusion for 
final analyses are summarised in the CONSORT diagram 
figure 1 and excluded studies and meta- analyses can be 
found in the supplementary references.
esMo-MCBs grading
Information for the selected trials is summarised in 
table 1 for fluoropyrimidine regimens and in table 2 for 
oxaliplatin added to fluoropyrimidine regimens. Results 
in the tables are categorised to combined stage II and III, 
stage II and stage III.
Fluoropyrimidine regimens
Four trials and a meta- analysis compared 5- FU/LV 
chemotherapy with MOF combination chemotherapy 
(lomustine (MeCCNU), vincristine and non- modulated 
5- FU))19 or surgery only for combined stage II and III 
colon cancers.20–23 They showed OS gain ranging from 
5% to 14% at 3.0–5.0 years, resulting in the highest- grade 
ESMO- MCBS garde (A). These results were confirmed 
in three successive meta- analyses by the Adjuvant Colon 
Cancer End- points (ACCENT) Group showing a 7.0%–
7.2% OS advantage at 5–8 years follow- up (grade A).24–26 
Since 5- FU/levamisole (LEV) was included in these meta- 
analyses, the OS benefit of 5- FU/LV was probably under-
estimated since LEV was subsequently found to be infe-
rior to LV as a 5- FU modulator.27–30 Table 1.
The two trials with 318 and 500 patients31 32 and a meta- 
analysis33 with 1016 patients evaluated adjuvant 5- FU/LV 
versus no adjuvant therapy in stage II colon cancer. None of 
these three studies demonstrated OS benefit and all were 
annotated as NEB. A 2004 meta- analysis involving 1440 
patients25 demonstrated a non- significant 5- year survival 
gain of 1% (ESMO- MCBS grade NEB), however, a subse-
quent 2009 evaluation by the same group26 with more 
mature data reported a 5.4% OS benefit at 8 years (grade 
A). This discrepancy is addressed in the discussion below.
In grade III colon cancer, the observed OS benefit was 
13.5% and 10.3% at 5 and 8 years, respectively, resulting 
in a grade A on the ESMO- MCBS.26 34
Uracil and tegafur (UFT)/LV in combined stage II 
and III colon cancer,35–37 capecitabine38 and S-139 40 in 
stage III colon cancer all did not provide an OS or DFS 
benefit compared with 5- FU/LV. Three of the four trials 
were non- inferiority trials. Although non- inferiority was 
proven, since neither QoL nor toxicity was improved; all 
studies were graded NEB.
Fluoropyrimidines with oxaliplatin combinations
Oxaliplatin added to 5- FU based regimens was evalu-
ated in the MOSAIC41 and NSABP C-0742 trials including 
stage II and III patients and the NO16968 trial confined 
to stage III patients.43 Greater clinical benefit (grade A) 
was observed in the trial confined to stage III compared 
with the other two trials which were graded B and NEB, 
respectively. The ACCENT group published a meta- 
analysis of these studies in 2016.44 Based on 5- year OS 
data their analysis demonstrated an insignificant 0.8% OS 
gain for stage II (NEB) and a 4.2% OS advantage for stage 
III colon cancer (grade B). Table 2.
In 2018 the International Duration Evaluation of Adju-
vant (IDEA) consortium reported the planned combined 
analysis of 6 individual RCTs, with a non- inferiority 
design, comparing folinic acid/5- FU/oxaliplatin 
(FOLFOX) and capecitabine/oxaliplatin (CAPOX) for 
3 vs 6 months.45 The 3- year DFS rate was very similar but 
non- inferiority was not proven for the intention to treat 
population resulting in a NNI. A preplanned subgroup 
analysis showed that 3 months CAPOX was non- inferior 
compared with 6 months. The 3 months treatment arm 
received a grade B based on non- inferiority in combina-
tion with less toxicity.46–48 T4 versus T1-3 and N2 versus N1 
subgroups were prespecified however their combinations 
in subgroups and its interaction test was not significant, 
thus these subgroup analyses were post hoc and could not 
be graded.
In one meta- analysis, in stage III patients, capecitabine 
with or without oxaliplatin versus 5- FU/LV with or without 
oxaliplatin was examined. As no OS and DFS benefit was 
seen, and neither QoL nor toxicity was improved, it was 
graded NEB.49
toxicity, Qol and cost
AT and LT reported in the included trials are summarised 
in the online supplementary table 1. All trials reported AT 
using several different approaches to toxicity evaluation: 
one trial did not use any grading system,50 five did NR the 
grading system used,19 22 26–29 five used the WHO toxicity 
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criteria for adverse events (CTCAE) V.1–3.36 38 41 42 44 45 
Reporting was more complete in the latest reported studies. 
The most recent IDEA consortium trial was the most 
complete in acute adverse events reporting, summarised 
in online supplementary table 1.45 This non- inferiority trial 
was the only trial in which AT data influenced the grade, 
as one prespecified subgroup with non- inferior efficacy was 
rewarded for having less AT to a B grade.
Reporting of LT was very limited. Five trials (two 
were individual trials within the IDEA collaboration), 
reported late sensory neuropathy graded with the CTCAE 
V.1–3.41–43 45–47 In all trials, this was investigator reported 
data and the assessment times and follow- up period 
differed. Overall, the reported prevalence of late neurop-
athy was low. With regard to oxaliplatin treatment dura-
tion, in the IDEA France trial, at a median follow- up of 3.6 
years, the prevalence of grade 3–4 neuropathy was 0.5% 
among patients exposed to 3 months of oxaliplatin versus 
2% among those who received 6 months of oxaliplatin.46 
In the ACHIEVE trial, at a median follow- up of 3 years, 
the prevalence all grade neuropathy was 23.3% vs 10%, 
while grade 3 was only 0.3 vs 0%.47 In the ACHIEVE trial, 
it was also observed that the incidence of any grade PSN 
was lower for patients treated with CAPOX compared 
with FOLFOX in both the 6 months and 3 months treat-
ment groups. All other studies did NR any LT.
QoL data were only available for 5 of the 20 RCT 
(one was an individual trial within the IDEA collabora-
tion).23 35–38 48 There was no consistency in the scales used. 
The only trial to report differences in QoL between the 
treatment arms was the SCOT trial of the IDEA consor-
tium which compared 3–6 months of oxaliplatin based 
adjuvant therapy. After 3 months to 5 years of follow- up, 
there was major difference (p<0.001) in neuropathy- 
related QoL evaluated using the Functional Assessment 
of Cancer Therapy/Gynecologic Oncology Group- 
Neurotoxicity questionnaire. Patients receiving 6 months 
oxaliplatin reported a worse QoL at 1, 3 and 5 years 
compared with those receiving 3 months oxaliplatin, and 
this disparity was associated with major differences in 
Global QoL between 3 and 6 months gradually attenu-
ating over subsequent months and years.48
None of the trials did a formal cost analysis and could 
therefore not be used for grading of non- inferiority trials. 
However, non- inferiority of a shorter treatment duration 
most likely leads to reduction in treatment cost.
expert peer review of the generated scores
Thirty- seven experts from the ESMO Gastro- Intestinal 
Tumours Faculty reviewed the generated scores. Twenty- 
five (67.6%) confirmed the reasonableness of the scores 
and 12 (34.4%) found the scores mostly reasonable. 
Experts pointed out that it was striking that the current 
recommended oxaliplatin- based treatment for stage III 
disease was only once graded with the highest A grade.
Two experts commented on non- inferiority trials that 
offer a similar efficacy despite evaluating a more conve-
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concern that the failure to reward this difference in 
convenience may fail to credit a true benefit. The ESMO- 
MCBS V.1.1 of form 1 does not offer the means to credit 
convenience.
dIsCussIon
This paper has evaluated the applicability of form 1 of 
the ESMO- MCBS V.1.1 to the adjuvant therapies for early 
colon cancer. Overall, the experience has been positive 
insofar as the scoring of adjuvant approaches in early 
colon cancer are considered reasonable (67.6%) or 
mostly reasonable (32.4%) by all experts.
For patients with stage III colon cancer, RCTs and meta- 
analyses of modulated 5- FU- based chemotherapy versus 
surgery only, consistently scored A in the ESMO- MCBS 
and the RCTs and meta- analysis comprising oxaliplatin 
added to this 5- FU backbone showed a modest additional 
OS benefit (grade B).
For stage II, the findings were less consistent. Whereas 
fluoropyrimidine trials in patients with stage II colon 
cancer consistently were graded NEB, the most recent 
meta- analysis demonstrated a 5.4% survival advantage 
after 8 years follow- up (grade A). The ACCENT inves-
tigators have subsequently cautioned that conclusions 
derived from older trials of FU- based adjuvant therapy 
in stage II colon cancer may be biased by stage migra-
tion over time.51 To date, there are no subgroup anal-
yses restricted to stage II in trials with patients that were 
adequately staged by contemporary standards. RCTs and 
meta- analysis adding oxaliplatin demonstrated no added 
benefit for patients with stage II colon cancer.
Several meta- analyses analysed efficacy in stage II/
III21 24–26 44 as well as separately in II25 26 32 44 or stage 
III.26 44 49 Four of these were performed by the ACCENT 
Collaborative Group24–26 44 which, as of 2016, included 
detailed information collected from over 40 000 patients 
from 27 adjuvant colon cancer trials including patient 
demographics and disease characteristics, treatment 
data, biomarkers for selected studies, adverse events, as 
well as log term recurrence and survival follow- up for all 
patients. This has facilitated the capacity to undertake 
robust analysis of pooled individual patient data in meta- 
analyses and in the evaluation of the validity of surrogate 
outcomes.52 53
Regarding the surrogacy of DFS as a predictor of OS, 
analysis by the ACCENT Collaborative Group demon-
strated a robust relationship for 2, 3, 5 and 6 years DFS 
and OS for stage III colon cancer52 53 but this was not 
the case for stage II disease and indeed even 6 years DFS 
was only weakly associated with OS.53 Consequently, they 
concluded that unless DFS is considered a clinically rele-
vant endpoint, OS should be regarded as the most appro-
priate endpoint for trials in unselected stage II disease.53
The ESMO- MCBS V.1.1 has no defined rules regarding 
the minimum quality perquisites for a meta- analysis to 
be evaluated. In future amendments of the scale, formal 
definitions of quality and improved clarity regarding the 
issue of multiplicity when there are several subgroup 
analysis will be important. In general, an impactful and 
valid meta- analysis should include at least the following 
ingredients: investigation of a plausible question based 
on randomised evidence using an exhaustive review of 
relevant studies; evaluation of consistency across studies 
regarding population of interest, relevant patient charac-
teristics and control arm, coupled with lack of bias (publi-
cation, selective reporting); exploration of heterogeneity 
and clear description of limitations.54
Reporting of toxicity and QoL effects of new adjuvant 
systemic treatment modalities, especially if long- lasting, is 
important to optimally inform patients. A penalty system 
for toxicities, such as used in the non- curative setting in 
the ESMO- MCBS V.1.1 (forms 2 and 3), is not appropriate 
for the curative setting (form 1) since patients may accept 
higher toxicity trade- off when treatment is with curative 
intent. Representatives of patient advocacy groups, in 
consultation with the ESMO- MCBS Working Group, have 
indicated preference for annotation of high likelihood of 
AT or LT versus penalties which may mask the magnitude 
of curative potential. We strongly believe toxicity annota-
tions should indeed be introduced for treatments with a 
high prevalence of AT and especially LT.
Our exploratory evaluation of toxicity highlighted that 
toxicity evaluation and annotation is challenging in the 
setting of inconsistent methods of toxicity reporting, 
a high prevalence of apparent under reporting and 
minimum reporting of LT. The chronic neurotoxicity 
induced by oxaliplatin is a cumulative, dose- dependent, 
sensory, symmetric distal axonal neuropathy.55 56 Tingling 
is the most prominent symptom, but numbness and pain 
can also occur.55 In our review of the toxicity data, late 
grade 3/4 PSN was reported in only 0.5%–2% of patients, 
substantially lower than the prevalence data derived from 
patient reported outcome data.54 This highlights the risk 
of under- reporting of toxicities by physicians.57 In addi-
tion, even several years after adjuvant oxaliplatin- based 
chemotherapy, in some situations distal neurotoxicity 
symptoms are reported as re- induced by cold tempera-
ture or repeated use of fingers like key- board typing, 
piano playing or exercising precise finger movements. 
This is general not mentioned in the toxicity report of 
clinical trial but has a potential negative impact on QoL 
or professional career.
In our analyses, only 5 out of 18 trials evaluated 
QoL.23 35–38 48 The low rate of inclusion of QoL evaluation 
has been examined in a study comprised by phase III RCTs 
in cancer performed between 2012 and 2016 published 
in 11 major journals. In 210 of the 446 trials (47.1%), 
QoL was not included as an endpoint. The non- inclusion 
was even higher for RCTs in (neo)adjuvant disease as 
81 of the 124 trials (65.3%) did not include QoL as an 
endpoint.58 Most of the adjuvant trials reporting QoL 
showed no difference between the investigational and 
control arm: 5- FU/LV or placebo,23 UFT/LV or 5- FU/
LV35–37 and capecitabine or 5- FU/LV.38 The findings of 
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at 1, 3 and 5 years for patients treated 6 vs 3 months were 
salient (p=<0.001).
UFT/LV did not show OS benefit35 and a non- inferior 
OS36 for stage II/III colon cancer compared with 5- FU/LV 
in two trials and neither QoL nor toxicity was improved. 
Both trials were graded NEB35–38 as was the trial of capecit-
abine versus 5- FU/LV.38 While it is plausible that oral 
medication may be more convenient than intravenous 
treatment, there are no data that it actually improves 
QoL compared with conventional parenteral administra-
tion. Convenience is not credited in the current version 
of form 1 of the ESMO- MCBS.
Our findings confirm that form 1 was highly applicable 
to the studies of adjuvant systemic therapies of early- stage 
colon cancer and it provided very reasonable grading 
for adjuvant colon cancer studies. The exploratory anal-
ysis indicated that toxicity annotation is feasible but the 
prevailing convention of physician reported toxicity may 
underestimate the true level of patient burden from both 
AT and LT. Since patients in the curative setting poten-
tially live decades after treatment, late and prolonged 
adverse effects that may undermine QoL should be anno-
tated to optimally inform patients of recognised risks. 
Future revisions of form 1 of the ESMO- MCBS will be 
cognoscente of these findings.
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